000 03686nam a22004815i 4500
001 978-3-642-23693-8
003 DE-He213
005 20140220083302.0
007 cr nn 008mamaa
008 120110s2012 gw | s |||| 0|eng d
020 _a9783642236938
_9978-3-642-23693-8
024 7 _a10.1007/978-3-642-23693-8
_2doi
050 4 _aRM281
050 4 _aQR189-189.5
072 7 _aMJCM
_2bicssc
072 7 _aMED044000
_2bisacsh
082 0 4 _a615.372
_223
100 1 _aKozlowski, Pamela A.
_eeditor.
245 1 0 _aMucosal Vaccines
_h[electronic resource] :
_bModern Concepts, Strategies, and Challenges /
_cedited by Pamela A. Kozlowski.
264 1 _aBerlin, Heidelberg :
_bSpringer Berlin Heidelberg,
_c2012.
300 _aX, 198p. 20 illus., 7 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aCurrent Topics in Microbiology and Immunology,
_x0070-217X ;
_v354
520 _aMost human pathogens utilize mucosal surfaces to access the host. This volume is focused on the development of vaccines which generate immune effectors capable of blocking mucosal entry or peripheral pathogen spread. A critical first step in the design of mucosal vaccines is the selection of administration route. Not all mucosal immunization routes are created equally when it comes to eliciting immune responses in multiple body compartments. This subject and situations when a mucosal route may not be required for vaccine delivery are reviewed here with an emphasis on the sublingual immunization route, which may offer a safer alternative to the nasal route for induction of broadly disseminated immune responses. External host defenses that inhibit entry of microorganisms at mucosal surfaces also pose obstacles to the efficient internalization of mucosally-applied vaccines. Transcutaneous immunization with appropriate adjuvants and permeation enhancers can induce mucosal immune responses and may be advantageous for bypassing these luminal barriers. Other chapters describe strategies for enhancing uptake of mucosal vaccines, for instance through targeted delivery to antigen-sampling M cells, construction of virus-like particles which mimic natural pathogens, addition of mucoadhesives or formulation as nanoparticles. Topics include edible vaccines as well as plant-based production of subunit or particulate vaccines that could be administered by any route. Dry powder vaccines that could be insufflated or directly applied to mucosal surfaces may be particularly ideal for mass vaccination in developing countries. The manufacture, stability and efficacy of powder formulations is comprehensively reviewed. We conclude with chapters on two of the greatest challenges facing mucosal vaccine development: human immunodeficiency virus and bioterrorist agents. This monograph highlights progress and information that should prove invaluable for the development of contemporary vaccines that prevent infection by these and other mucosal pathogens.
650 0 _aMedicine.
650 0 _aImmunology.
650 0 _aMonoclonal antibodies.
650 0 _aVaccines.
650 1 4 _aBiomedicine.
650 2 4 _aVaccine.
650 2 4 _aImmunology.
650 2 4 _aAntibodies.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9783642236921
830 0 _aCurrent Topics in Microbiology and Immunology,
_x0070-217X ;
_v354
856 4 0 _uhttp://dx.doi.org/10.1007/978-3-642-23693-8
912 _aZDB-2-SBL
999 _c102212
_d102212